Portfolio
The founders we back.
Hover over a company to learn more, or select it to visit its website.
Fund I Initial Investments
Companies held by our General Partner for warehouse transfer into Inuksuk Health Opportunities Fund I (IHOFI) at its first close.
Eradivir
A small-molecule bispecific immunotherapy platform that directs the immune system to clear viruses and other disease-causing cells.
Hexembio
Regenerative stem cell therapies designed to restore healthy blood stem cell function in aging patients.
Qaelon Medical
A smart insufflator that detects surgical leaks during minimally invasive surgery, before they become post-operative complications.
Team Track Record
Investments made by members of the Inuksuk Ventures team individually or through prior vehicles. These companies are not holdings of the fund.
Atrin Pharmaceuticals
Precision oncology company developing ATR and WEE1 inhibitors for solid tumors. Acquired by Aprea Therapeutics in May 2022 for $76.2 million.
Felicitex Therapeutics
Drug discovery company developing treatments for dormant, therapy-resistant cancers.
Cassian Solutions
Specialty care management software and smart medication cases that help patients take their medications on schedule.
Adipoligo Health Sciences
Synthetic RNA therapeutics for cardiovascular disease, with a focus on lipid metabolism.